These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23474033)

  • 1. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
    Zhao Y; Alakhova DY; Kim JO; Bronich TK; Kabanov AV
    J Control Release; 2013 May; 168(1):61-9. PubMed ID: 23474033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
    Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
    J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
    Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
    Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers.
    Hong W; Chen D; Zhang X; Zeng J; Hu H; Zhao X; Qiao M
    Biomaterials; 2013 Dec; 34(37):9602-14. PubMed ID: 24021757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
    Zou Y; Meng F; Deng C; Zhong Z
    J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
    Li L; ten Hagen TL; Haeri A; Soullié T; Scholten C; Seynhaeve AL; Eggermont AM; Koning GA
    J Control Release; 2014 Jan; 174():202-8. PubMed ID: 24269966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
    Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
    PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site.
    Silverman L; Barenholz Y
    Nanomedicine; 2015 Oct; 11(7):1841-50. PubMed ID: 26115641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
    Apte A; Koren E; Koshkaryev A; Torchilin VP
    Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation of Stimuli-Responsive and Stoichiometrically Controlled Release Rate of Doxorubicin from Liposomes in Tumor Interstitial Fluid.
    Yamamoto E; Hyodo K; Suzuki T; Ishihara H; Kikuchi H; Kato M
    Pharm Res; 2018 Mar; 35(5):103. PubMed ID: 29557075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.